Veronica Byfield Sköld
Algemeen Directeur bij BioLamina AB
Profiel
Veronica Byfield Sköld is currently the Chief Executive Officer at BioLamina AB.
Previously, she worked as the Chief Sales Officer at Clemondo Group AB.
She holds a graduate degree from the Royal Institute of Technology and an undergraduate degree from IHM Business School AB.
Actieve functies van Veronica Byfield Sköld
| Bedrijven | Functie | Begin |
|---|---|---|
BioLamina AB
 BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden. | Algemeen Directeur | 01-10-2021 |
Eerdere bekende functies van Veronica Byfield Sköld
| Bedrijven | Functie | Einde |
|---|---|---|
| CLEMONDO GROUP AB | Verkoop & Marketing | - |
Opleiding van Veronica Byfield Sköld
| Royal Institute of Technology | Graduate Degree |
| IHM Business School AB | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CLEMONDO GROUP AB | Consumer Non-Durables |
| Bedrijven in privébezit | 1 |
|---|---|
BioLamina AB
BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden. | Health Technology |
